Oncocyte Corporation Aktie News

IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion t...

OncoCyte Corporation (NASDAQ:OCX ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President & Chief Executive Officer Andrea James - Chief Financial Officer Ekke Schutz - Chief Science Officer Conference Call Participants Mark Massaro - BTIG Mason Carrico - Stephens Thomas Flaten - Lake Street Mike Mat...

IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results:

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025.

IRVINE, Calif., May 7, 2025 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025.

IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market.

Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the ...

IRVINE, Calif., April 2, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025.